Affiliation:
1. Division of Medicinal Chemistry, Otto Loewi Research, Medical University of Graz, 8010 Graz, Austria
2. Division of Transplantation Surgery, Medical University of Graz, 8010 Graz, Austria
3. Institut für Laborwissenschaft Dr. Greilberger, Schwarzl Medical Center, 8053 Lassnitzhoehe, Austria
4. Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria
Abstract
N-acetyl-selenomethionine (NASeLM), a representative of the selenium compounds, failed to convince in clinical studies and cell cultures that it neither inhibits cancer growth nor has a chemoprotective effect. This study aims to find out whether NASeLM shows a growth-inhibiting property compared to the carrier substance N-Acetyl-L-methionine (NALM) on two different cancer cells, namely Jurkat cells and MTC-SK cells. Methods: Jurkat and MTC-SK cells were cultured in the absence or presence of varying concentrations (0–500 µg/mL) of NASeLM and NALM solutions. After 0, 24, 48, and 72 h, mitochondrial activity, cancer cell membrane CP levels, cell growth, and caspase-3 activity were assessed in aliquots of Jurkat and MTC-SK cells. Results: Both substances, NASeLM and NALM, were similarly able to inhibit cell growth and mitochondrial activity of Jurkat cells in a concentration-dependent and time-dependent manner up to 70%. Only the determination of caspase activity showed that only NASeLM was able to increase this to almost 40% compared to the control as well as the same lack of NALM. However, the experiments on MTC-SK cells showed a clear difference in favor of NASeLM compared to NALM. While NASeLM was able to reduce cell growth to up to 55%, the same amount of NALM was only at around 15%, which turned out to be highly significant (p < 0.001). The same could also be measured for the reduction in MTC-SK mitochondrial activity. Time dependence could also be recognized: the longer both substances, NASeLM and NALM, were incubated, the higher the effect on cell growth and mitochondrial activity, in favour of NASeLM. Only NASeLM was able to increase caspase-3 activity in MTC-SK cells: at 250 µg/mL NASeLM, caspase-3 activity increased significantly to 28% after 24 and 48 h compared to the control (14%) or the same NALM concentration (14%). After 72 h, this could still increase to 37%. A further increase in the NASeLM concentration did not result in higher caspase-3 activity. Conclusion: NASeLM could clearly increase caspase-3 activity in both cell types, Jurkat or MTC-SK cells, and thus induce cell death. NALM and NASeLM showed a reduction in cell growth and mitochondrial activity in both cell lines: While NALM and NASeLM showed almost identical measurements on Jurkat cells, NASeLM was much more effective on MTC-SK than the non-selenium-containing carrier, indicating that it has additional anti-chemoprotective effects.
Reference21 articles.
1. Radomska, D., Czarnomysy, R., Radomski, D., and Bielawski, K. (2021). Selenium Compounds as Novel Potential Anticancer Agents. Int. J. Mol. Sci., 22.
2. Chapeter Ten—Selenocompounds in cancer therapy: An overview;Bartolini;Adv. Cancer Res.,2017
3. Selenium and selenoproteins: It’s role in regulation of inflammation;Hariharan;Inflammopharmacology,2020
4. The association between serum selenium levels and pathological features of papillary thyroid cancer in 284 patients;Ge;Front. Endocrinol.,2023
5. Selenium, folate, and colon cancer;Poole;Nutr. Cancer,2009